[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA2078700A1 - Imidazolylmethyl-pyridines - Google Patents

Imidazolylmethyl-pyridines

Info

Publication number
CA2078700A1
CA2078700A1 CA002078700A CA2078700A CA2078700A1 CA 2078700 A1 CA2078700 A1 CA 2078700A1 CA 002078700 A CA002078700 A CA 002078700A CA 2078700 A CA2078700 A CA 2078700A CA 2078700 A1 CA2078700 A1 CA 2078700A1
Authority
CA
Canada
Prior art keywords
imidazolylmethyl
pyridines
formula
alzheimer
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002078700A
Other languages
French (fr)
Other versions
CA2078700C (en
Inventor
Rudolf Karl Andreas Giger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2078700A1 publication Critical patent/CA2078700A1/en
Application granted granted Critical
Publication of CA2078700C publication Critical patent/CA2078700C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Luminescent Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compounds of formula I, (see formula I) wherein R1 to R4 possess the significances given in the description, may be used in the treatment of senile dementia, Alzheimer's disease and depression.
CA002078700A 1991-09-23 1992-09-21 Imidazolylmethyl-pyridines Expired - Fee Related CA2078700C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4131584A DE4131584A1 (en) 1991-09-23 1991-09-23 IMIDAZOLYLMETHYL-PYRIDINE, THEIR PRODUCTION AND USE AS A PHARMACEUTICAL
DEP4131584.7 1991-09-23

Publications (2)

Publication Number Publication Date
CA2078700A1 true CA2078700A1 (en) 1993-03-24
CA2078700C CA2078700C (en) 2005-09-13

Family

ID=6441240

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002078700A Expired - Fee Related CA2078700C (en) 1991-09-23 1992-09-21 Imidazolylmethyl-pyridines

Country Status (24)

Country Link
EP (1) EP0534904B1 (en)
JP (1) JP2568356B2 (en)
KR (1) KR100254085B1 (en)
AT (1) ATE144509T1 (en)
AU (1) AU650569B2 (en)
CA (1) CA2078700C (en)
CZ (1) CZ281675B6 (en)
DE (2) DE4131584A1 (en)
DK (1) DK0534904T3 (en)
ES (1) ES2092666T3 (en)
FI (1) FI103887B (en)
GR (1) GR3021444T3 (en)
HU (2) HUT61993A (en)
IL (1) IL103229A (en)
MX (1) MX9205365A (en)
MY (1) MY110450A (en)
NO (1) NO301162B1 (en)
NZ (1) NZ244420A (en)
RO (1) RO109337B1 (en)
RU (1) RU2058312C1 (en)
SG (1) SG43079A1 (en)
SK (1) SK279224B6 (en)
TW (1) TW222630B (en)
ZA (1) ZA927279B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10165349A (en) * 1996-12-06 1998-06-23 Matsushita Electric Ind Co Ltd Dish washer
DE10000161A1 (en) * 2000-01-06 2001-07-19 Boehringer Ingelheim Pharma Determining test substances that inhibit protease, involves incubating cells expressing fusion protein having substrate with cleavage site for protease and reporter, measuring cleaved reporter and comparing with standard
GB0009037D0 (en) * 2000-04-13 2000-05-31 Novartis Ag Organic compounds
CA2616177C (en) * 2005-07-29 2012-05-01 Vanda Pharmaceuticals, Inc. Imidazolylalkyl-pyridines for the treatment of a sleep disorder
CN101394849A (en) * 2006-02-13 2009-03-25 Vanda制药公司 Stable dosage formulations of imidazolylalkyl-pyridines
WO2009097416A1 (en) * 2008-01-29 2009-08-06 Vanda Pharmaceuticals, Inc. Imidazolylalkyl- pyridines as dbh inhibitors
KR20110071014A (en) 2008-10-17 2011-06-27 위스콘신 얼럼나이 리서어치 화운데이션 Method of making biologically active alpha-beta peptides
US9394290B2 (en) * 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
US20200179361A1 (en) * 2017-05-22 2020-06-11 Torrey Pines Institute For Molecular Studies Compositions, methods of use, and methods of treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0003732B1 (en) * 1978-02-01 1983-10-19 The Wellcome Foundation Limited Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations thereof
GB2028317B (en) * 1978-08-15 1982-11-10 Pfizer Ltd 2-(imidazol-1-ylmethyl)-pyridine and -quinoline thromboxane synthetase inhibitors
US4634711A (en) * 1985-08-02 1987-01-06 Smithkline Beckman Corporation Pyridylalkyl imidazole-2-thiols
DE3811574A1 (en) * 1988-03-31 1989-10-19 Schering Ag N-SUBSTITUTED IMIDAZOLES, METHODS FOR THEIR PRODUCTION AND THEIR USE IN MEDICINAL PRODUCTS

Also Published As

Publication number Publication date
RU2058312C1 (en) 1996-04-20
DE4131584A1 (en) 1993-03-25
HU211261A9 (en) 1995-11-28
CZ289692A3 (en) 1993-04-14
TW222630B (en) 1994-04-21
KR930006003A (en) 1993-04-20
AU2522692A (en) 1993-03-25
CA2078700C (en) 2005-09-13
ATE144509T1 (en) 1996-11-15
EP0534904A1 (en) 1993-03-31
ZA927279B (en) 1994-03-23
JP2568356B2 (en) 1997-01-08
HUT61993A (en) 1993-03-29
DE59207425D1 (en) 1996-11-28
NO923653D0 (en) 1992-09-21
NZ244420A (en) 1995-07-26
FI103887B1 (en) 1999-10-15
HU9202886D0 (en) 1992-11-30
GR3021444T3 (en) 1997-01-31
EP0534904B1 (en) 1996-10-23
JPH05194491A (en) 1993-08-03
KR100254085B1 (en) 2000-09-01
DK0534904T3 (en) 1996-11-18
ES2092666T3 (en) 1996-12-01
MY110450A (en) 1998-05-30
FI924233A0 (en) 1992-09-21
NO923653L (en) 1993-03-24
FI924233A (en) 1993-03-24
IL103229A (en) 1996-09-12
RO109337B1 (en) 1995-01-30
IL103229A0 (en) 1993-02-21
SK289692A3 (en) 1998-08-05
SK279224B6 (en) 1998-08-05
MX9205365A (en) 1993-03-01
NO301162B1 (en) 1997-09-22
AU650569B2 (en) 1994-06-23
FI103887B (en) 1999-10-15
CZ281675B6 (en) 1996-12-11
SG43079A1 (en) 1997-10-17

Similar Documents

Publication Publication Date Title
EP0423714A3 (en) Hair revitalizing agent
AU7068687A (en) Oxadiazoles useful in the treatment of senile dementia
MY111556A (en) Substituted azadioxacycloalkenes.
HUT45692A (en) Acaricide compositions containing 1-aralkyl-pyrazoles as active components and process for producing the new active components
CA2195213A1 (en) Use of droloxifene for the treatment of cardiovascular diseases
CA2172513A1 (en) Aminocyclohexylesters and uses thereof
CA2051855A1 (en) Process for producing n-substituted-1-deoxynojirimycin
CA2194885A1 (en) Substituted benzamidines, their preparation and their use as pharmaceutical compounds
HUT47369A (en) Acaricide and fungicide compositions containing substituted 1,4-naphtoquinones and process for producing the active components
CA2138289A1 (en) N-substituted azabicycloheptane derivatives, the preparation and use thereof
CA2019231A1 (en) Novel acetylcholinesterase inhibitors
CA2078700A1 (en) Imidazolylmethyl-pyridines
AU1674492A (en) Alzheimer's disease treatment with tacrine metabolites
HK1020317A1 (en) Use of 2-phenyl 1-1,2-benzisoselenazol3(2h)-one for producing a pharmaceutical preparation intended for treatment of the alzheimer's disease
AU1413788A (en) Dihydropyridinamides process for their preparation, and their use in medicaments
CA2047802A1 (en) Pharmaceutical compositions
WO1991015466A3 (en) Aminopolycarboxylic acid chelating agents
EP0492478A3 (en) Tert-butyloxycarbonyl-l-tyrosyl-peptidoglycan monomer and 125 i-labelled derivative thereof, their preparation and use
CA2032303A1 (en) Inhibitors of retroviral proteases
MY108199A (en) Tricyclic pyridone derivative
AU3084992A (en) 1,4-dihydropyridines for use in the treatment of dermatosis
HUT59903A (en) Fungicide compositions containing oxime-carbamates as active components and process for producing the active components
USD346749S (en) Clock
CA2138288A1 (en) Substituted azabicycloheptane derivatives, their preparation and use
MY102415A (en) Pilocarpine derivatives

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed